Senators call on USPTO to address pharma patent thickets before they start

Zachary Brennan

Senior Editor

Three Republican and three Democrat senators on Wednesday called on the US Patent and Trademark Office to attack pharma patent thickets before they start. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senators call on USPTO to address pharma patent thickets before they start

Zachary Brennan

Senior Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Exclusive: Florida cancer biotech raises $100M Series A

Sen­a­tors call on USP­TO to ad­dress phar­ma patent thick­ets be­fore they start

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Senators call on USPTO to address pharma patent thickets before they start

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Exclusive: Florida cancer biotech raises $100M Series A